Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 19/20 | 1.00 |
| ▸ | TLR8 known ✓ | Q9NR97 | 12/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resiquimod SCHEMBL29358122 | 1.00 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL21352711 | 1.00 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2266073 | 0.99 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2262583 | 0.99 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| SCHEMBL24880278 | 0.94 | TLR7 (0.88) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL22158700 | 0.93 | TLR7 (0.86) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL17190806 | 0.93 | TLR7 (0.86) | TLR7TLR8NUDT1 | |
| SCHEMBL6718996 | 0.92 | TLR7 (0.84) | TLR7TLR8NUDT1 | |
| SCHEMBL20199817 | 0.91 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| SCHEMBL5454764 | 0.90 | TLR7 (0.82) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21397 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993771-B1 | SONODYNAMIC THERAPY | INNOVATION ULSTER LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| US-20260139063-A1 | PRE-MEDICATION AND IMPROVED TREATMENT REGIMEN | MONTA BIOSCIENCES APS (DK) | 2026-05-21 | — | — | US | claimed |
| EP-4743119-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING TGFB ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | Nammi Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122031668-A | Formulations for neoplasia vaccines | 博德研究所 | 2026-05-15 | — | — | CN | claimed |
| EP-3641771-B1 | COMPOSITIONS COMPRISING CRYSTALLINE RESIQUIMOD MONOSULFATE ANHYDRATE SALT OR OTHER RESIQUIMOD CRYSTALLINE SALTS OR OTHER CRYSTALLINE SALTS OF 1H-IMIDAZO-[4,5-C]-QUINOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2026-05-13 | — | — | EP | claimed |
| CN-122005785-A | Method for identifying HIV patients susceptible to therapy with GP 120V 3 glycan-directed antibodies | 吉利德科学公司 | 2026-05-12 | — | — | CN | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | claimed |
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260116918-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | claimed |
| US-20260115313-A1 | ANTIBODY-CONJUGATED LIPOSOME | HIGHFIELD BIOPHARMACEUTICALS CORPORATION (CN) | 2026-04-30 | — | — | US | claimed |
| US-6039969-A | TH2 CELL MEDIATED DISEASE BACTERICIDES, ANTICARCINOGENIC AGENTS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-03-21 | — | — | US | claimed |
| EP-0942724-A2 | GEL FORMULATIONS FOR TOPICAL DRUG DELIVERY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0938315-A1 | IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2 MEDIATED AND RELATED DISEASES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-09-01 | — | — | EP | claimed |
| US-5939090-A | OF THE DRUG 4-AMINO-2-ETHOXYMETHYL-.ALPHA.,.ALPHA.-DIMETHYL-1H-IMIDAZO(4,5 -C)QUINOLINE-1-ETHANOL, WHICH WHEN APPLIED TOPICALLY INDUCES CYTOKINES, SUCH AS INTERFERON AND TUMOR NECROSIS FACTOR, | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-08-17 | — | — | US | claimed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998024436-A2 | GEL FORMULATIONS FOR TOPICAL DRUG DELIVERY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-06-11 | — | — | WO | claimed |
| WO-1998017279-A1 | IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2 MEDIATED AND RELATED DISEASES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-30 | — | — | WO | claimed |
| EP-0636031-B1 | VACCINE ADJUVANT | MINNESOTA MINING & MFG (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0636031-A1 | VACCINE ADJUVANT. | MINNESOTA MINING & MFG (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1993020847-A1 | VACCINE ADJUVANT | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-28 | — | — | WO | claimed |